MAPT and early-onset autosomal dominant Alzheimer disease: Small molecules that raise cAMP have therapeutical promise because they enhance the capacity of cell cultures [220] and mouse brains [119,226] to degrade misfolded proteins such as tau, which has been implicated in the pathogenesis of Alzheimer’s disease.